Table V.
Risk of all-cause and breast cancer-specific mortality by race/ethnicity, adjusting for socioeconomic status, tumor stage and triple-negative status.
| Hazard ratio (95% CI) of all-cause mortality | Hazard ratio (95% CI) of breast cancer-specific mortality | |||
|---|---|---|---|---|
| Characteristic | Crude model | Adjusted model | Crude model | Adjusted model |
| Race/ethnicity | ||||
| NH white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| NH black | 1.57 (1.53-1.61)a | 1.16 (1.12-1.19)a | 1.95 (1.89-2.02)a | 1.19 (1.15-1.23)a |
| NH Asian | 0.67 (0.64-0.69)a | 0.77 (0.74-0.80)a | 0.79 (0.75-0.84)a | 0.82 (0.78-0.87)a |
| Hispanic white | 0.93 (0.90-0.96)a | 0.93 (0.90-0.96)a | 1.19 (1.14-1.23)a | 0.97 (0.92-1.01) |
| Hispanic other | 1.12 (0.97-1.30) | 1.10 (0.95-1.28) | 1.49 (1.24-1.77)a | 1.15 (0.96-1.38) |
| Tumor stage | ||||
| Local | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Regional | 2.21 (1.99-2.07)a | 1.77 (1.73-1.81)a | 4.07 (3.95-4.21)a | 2.83 (2.73-2.93)a |
| Distant | 12.50 (12.22-12.81)a | 5.04 (4.89-5.20)a | 33.06 (32.00-34.16)a | 10.22 (9.80-10.66)a |
| Unknown | 6.61 (6.15-7.10)a | 1.56 (1.45-1.69)a | 11.04 (10.00-12.19)a | 2.35 (2.11-2.61)a |
| Triple-negative status | ||||
| HR+/HER2+ | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| HR+/HER2- | 0.88 (0.86-0.91)a | 1.07 (1.03-1.10)a | 0.69 (0.67-0.72)a | 1.13 (1.09-1.18)a |
| HR-/HER2+ | 1.44 (1.37-1.51)a | 1.33 (1.27-1.39)a | 1.67 (1.57-1.76)a | 1.43 (1.36-1.52)a |
| HR-/HER2- (triple-negative) | 1.99 (1.91-2.05)a | 2.24 (2.16-2.32)a | 2.31 (2.21-2.41)a | 2.87 (2.74-2.99)a |
| Race stratified by triple-negative status | ||||
| HR-/HER2- (triple-negative) | ||||
| NH white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| NH black | 1.39 (1.29-1.51)a | 1.19 (1.09-1.30)a | 1.59 (1.45-1.76)a | 1.25 (1.12-1.39)a |
| NH Asian | 0.64 (0.56-0.72)a | 0.79 (0.69-0.90)a | 0.71 (0.61-0.83)a | 0.82 (0.70-0.97)a |
| Hispanic white | 0.85 (0.77-0.93)a | 0.89 (0.81-0.99)a | 1.09 (0.97-1.22) | 1.02 (0.90-1.16) |
| Hispanic other | 0.97 (0.63-1.51) | 1.10 (0.70-1.71) | 0.90 (0.50-1.63) | 0.82 (0.45-1.49) |
| HR-/HER2+ | ||||
| NH white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| NH black | 1.53 (1.48-1.58)a | 1.19 (1.15-1.24)a | 1.96 (1.87-2.05)a | 1.25 (1.19-1.32)a |
| NH Asian | 0.62 (0.59-0.65)a | 0.74 (0.70-0.78)a | 0.76 (0.71-0.82)a | 0.80 (0.74-0.86)a |
| Hispanic white | 0.88 (0.84-0.92)a | 0.91 (0.87-0.95)a | 1.12 (1.06-1.19)a | 0.94 (0.89-0.99)a |
| Hispanic other | 1.12 (0.93-1.36) | 1.21 (0.99-1.46) | 1.68 (1.34-2.12)a | 1.40 (1.11-1.77)a |
| HR+/HER2- | ||||
| NH white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| NH black | 1.26 (1.14-1.39)a | 1.10 (0.99-1.23) | 1.42 (1.26-1.59)a | 1.21 (1.06-1.37)a |
| NH Asian | 0.67 (0.59-0.77)a | 0.87 (0.75-1.01) | 0.74 (0.63-0.87)a | 0.93 (0.78-1.10) |
| Hispanic white | 0.90 (0.80-1.01) | 1.04 (0.92-1.19) | 1.01 (0.88-1.16) | 1.09 (0.94-1.27) |
| Hispanic other | 1.11 (0.65-1.87) | 1.11 (0.65-1.88) | 1.59 (0.94-2.69) | 1.43 (0.84-2.44) |
| HR+/HER2+ | ||||
| NH white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| NH black | 1.23 (1.17-1.29)a | 1.05 (0.99-1.11) | 1.32 (1.24-1.40)a | 1.08 (1.01-1.15)a |
| NH Asian | 0.81 (0.74-0.88)a | 0.84 (0.76-0.93)a | 0.85 (0.77-0.95)a | 0.83 (0.74-0.93)a |
| Hispanic white | 0.97 (0.91-1.04) | 0.92 (0.86-0.99)a | 1.11 (1.03-1.20)a | 0.94 (0.86-1.02) |
| Hispanic other | 0.98 (0.71-1.36) | 0.84 (0.61-1.17) | 0.97 (0.65-1.43) | 0.77 (0.52-1.14) |
Adjusted for age, marital status, tumor stage, size, grade, year of diagnosis, SEER registry, health insurance, household income at county level, surgery, radiation and chemotherapy.
aP<0.05. NH, non-Hispanic; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.